InvestorsHub Logo
Followers 0
Posts 2865
Boards Moderated 0
Alias Born 10/31/2006

Re: lamboo39 post# 3679

Monday, 10/23/2017 8:23:33 PM

Monday, October 23, 2017 8:23:33 PM

Post# of 12519
Great Find!!!!

I like these 2 paragraphs:

At some point, soon I see PKTX as a prime takeover candidate. Likely won’t happen until trial results begin to come out, which I would expect to see sometime in early in 2018. Novo Nordisk, (NYSE:NVO) and Eli Lilly, (NYSE:LLY) are both active in the Type 1 diabetes space and would be on the list of companies interested in acquiring them.

And:

It should also be noted that the CEO has funded a significant amount of the development himself, and owns 24% of the Company, and is only paying himself a salary of $1. That is unheard of among small-cap biotechs. Most of often a management team owns very little stock and pays themselves exorbitant salaries. It’s nice to see a management team be “all-in” like the folks at PKTX. With no debt and an extremely small burn, there is very little downside to the stock at this point. At these levels, it is a great place to accumulate and hold until we begin to see the data from the trials.